Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac ® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study.

Phoom NarongkiatikhunKajohnsak NoppakunRomanee ChaiwarithPoramed WinichakoonSurachet VongsanimYuttitham SuteekaKarn PongsuwanPrit KusirisinNuttanun WongsarikanKanda FanhchaksaiChantana KhamwanDararat DankaiVuddhidej Ophascharoensuk

Published in: Vaccines (2023)

Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime-boost seemed to be more efficacious in terms of inducing immunogenicity.

Keyphrases

end stage renal disease
ejection fraction
immune response
newly diagnosed
chronic kidney disease
peritoneal dialysis
dna damage
dna repair
saccharomyces cerevisiae
cross sectional